Article published Sep 28, 2026. Prices below use latest available snapshots.
TMO Price Structure
Loading timeframes…
$TMO is doing well: up 34.0% since June 29 and up 9.1% since August 28, 25.5% above its 200-day average, and up 46.9% over the past year. At the 2026-09-28 settled close, TMO $678.60 was +6.8% versus its 20-day average and +9.1% over 30 days. The newest verified quarter ends 2026-06-27 (filed 2026-07-31); revenue was $11.99B. Against 2025-06-28 revenue of $10.86B, that is +10.5% year over year. Price is near the high with RSI above 70; academic and government demand is soft per the same coverage. The standing call is 🟡 Wait for a pullback. Entry $630–$650 on a flag that holds the September 11 close ($609.82) · stop $598 · first target $700 · medium conviction.
Quick Snapshot (as of 2026-09-28)
| Question | Answer |
|---|---|
| The call | 🟡 Wait for a pullback. Entry $630–$650 on a flag that holds the September 11 close ($609.82) · stop $598 · first target $700 · medium conviction |
| What is Thermo Fisher? | A leading supplier of lab instruments, consumables and outsourced drug-development services to pharma, biotech, academic and diagnostic customers. |
| Why look now? | Prior case (2026-09-23): Coverage in the September 18 news pull reports Q2 revenue up 10% to $11.99B, adjusted EPS up 13% to $6.03, a raised full-year outlook and a $1B buyback, plus a reported $9.1B acquisition of Clario. |
| What is the proof? | Latest verified period ended 2026-06-27, filed 2026-07-31: revenue $11.99B. Prior case: The reported quarter above is news-carried; the filing cache still ends at the March quarter, so the numbers are single-source here. |
| What is the objection? | Price is near the high with RSI above 70; academic and government demand is soft per the same coverage. |
| Stock setup | The long trend remains intact; +6.8% versus the 20-day, +25.5% versus the 200-day, RSI 73.5. |
Action Matrix (reviewed 2026-09-28; levels are standing conditions)
| Signal | Condition | Level | Why |
|---|---|---|---|
| 🟡 Wait | RSI above 70 at the high | — | The trend is right; the entry is late |
| 🟢 Buy | A pullback that holds above the September 11 close | $630–$650 | September 11 was the last pullback low before this leg |
| 🟠 Target | First target | $700 | A round planning level above the 52-week high, not a chart level |
| 🔴 Out | A close below the September 11 close | $609.82 | Loses the last higher low |
| 🔴 Thesis breaks | A guidance cut or a failed Clario close | — | The re-rating is being paid for accelerating growth |
The Story Right Now (as of 2026-09-28)
$TMO is doing well: up 34.0% since June 29 and up 9.1% since August 28, 25.5% above its 200-day average, and up 46.9% over the past year.
Data as of 2026-09-28 close: TMO $678.6, RSI 73.5, strong-up, +6.8% vs SMA20, +25.5% vs SMA200, 7D +3.0%, 30D +9.1%, 1Y +46.9%, -0.6% from the 52-week high.
Business and mechanism. A leading supplier of lab instruments, consumables and outsourced drug-development services to pharma, biotech, academic and diagnostic customers.
Prior case (2026-09-23). Coverage in the September 18 news pull reports Q2 revenue up 10% to $11.99B, adjusted EPS up 13% to $6.03, a raised full-year outlook and a $1B buyback, plus a reported $9.1B acquisition of Clario.
Prior proof (2026-09-23). The reported quarter above is news-carried; the filing cache still ends at the March quarter, so the numbers are single-source here.
The countercase. Price is near the high with RSI above 70; academic and government demand is soft per the same coverage.
Newest statement check. The newest verified quarter ends 2026-06-27 (filed 2026-07-31); revenue was $11.99B. Against 2025-06-28 revenue of $10.86B, that is +10.5% year over year.
News and attention check. The news search for the latest move failed; the last completed search was on 2026-09-18. No company event for TMO was recorded between September 24 and 28.
The call: 🟡 Wait for a pullback. Entry $630–$650 on a flag that holds the September 11 close ($609.82) · stop $598 · first target $700 · medium conviction.
Extended analysis
Price Data (live — latest settled close)
A live table: every cell shows the latest settled close, named in the first row. Dated readings live in the Research Log.
| Metric | Value |
|---|---|
| As of (settled close) | 2026-10-16 |
| Price ($) | 690 |
| RSI (14) | 64 |
| 20-day average ($) | 668.35 |
| vs 20-day (%) | 3.2 |
| 50-day average ($) | 636.69 |
| vs 50-day (%) | 8.4 |
| 200-day average ($) | 547.32 |
| vs 200-day (%) | 26.1 |
| 1D (%) | -0.93 |
| 7D (%) | 4.86 |
| 30D (%) | 6.41 |
| 3M (%) | 29.58 |
| 1Y (%) | 28.54 |
| 1Y vs benchmark (points) | 13.01 |
| From 52-week high (%) | -1.99 |
Financial Proof
Filed-period check (as of 2026-09-28): The newest verified quarter ended 2026-06-27 and was filed 2026-07-31. Revenue was $11.99B; GAAP net income was $1.74B; diluted EPS was 4.68. Source: Massive income statements and the filing. Dated historical tables below retain their own period basis.
The recent filed revenue series shows the direction of the business; missing cells are left unavailable.
| Period end | Revenue | YoY | Operating income | GAAP net income | Filing date |
|---|---|---|---|---|---|
| 2024-09-28 | $10.60B | — | $1.84B | $1.63B | 2024-11-01 |
| 2025-03-29 | $10.36B | — | $1.72B | $1.51B | 2025-05-02 |
| 2025-06-28 | $10.86B | — | $1.83B | $1.62B | 2025-08-01 |
| 2025-09-27 | $11.12B | +4.9% | $1.94B | $1.62B | 2025-10-31 |
| 2026-03-28 | $11.01B | +6.2% | $1.86B | $1.66B | 2026-05-01 |
| 2026-06-27 | $11.99B | +10.5% | $2.09B | $1.74B | 2026-07-31 |
Research Log
| Date | Update |
|---|---|
| 2026-05-29 | TMO $492.51, RSI 62.3, weak-up; +2.83% 30D (was flat at $499.23 on Apr 10). No new fundamentals re-researched. |
| 2026-06-16 | TMO $472.63, RSI 50.1; -3.47% 7D, +7.04% 30D, +0.08% 3M, +0.4% above SMA20. Returned to neutral from approaching-overbought May 29 reading. Hugging SMA20 — no directional signal. From 52wk high -26.61%. No new fundamentals re-researched. |
| 2026-07-11 | TMO $527.05, RSI 64.7, trend up; +3.21% 7D, +10.92% 30D, now +6.5% above SMA20 and essentially at SMA200 (+0.1%) for the first time in this series — regime reads "basing." From 52wk high narrowed to -18.16%. No new fundamentals re-researched. |
| 2026-07-17 | TMO $532.48, RSI 62.3, trend up; +1.03% 7D, +14.61% 30D, now +0.8% above SMA200 for the first time in this series. From 52wk high narrowed to -17.32%. No new fundamentals re-researched. |
| 2026-07-25 | TMO $568.26, RSI 71, crossed overbought for the first time in this series; +6.72% 7D, +15.45% 30D, +21.1% 3M, now +7.5% above SMA200 (widened from +0.8%). From 52wk high narrowed to -11.13%. Per MarketBeat (2026-07-23), the move follows a strong Q2 print and raised full-year outlook. |
| 2026-07-28 | TMO $576.41, RSI 70.3, still overbought; +10.12% 7D, +13.82% 30D, +23.75% 3M, now +9% above SMA200 (further extended). From 52wk high narrowed to -10.49%. Regime now reads "uptrend," matching price action. No new fundamentals re-researched. |
| 2026-07-31 | TMO $574.30, RSI 68.8, up; 7D +1.06%; 30D +11.88%; 3M +22.52%; -10.82% from 52wk high. No new fundamentals re-researched. |
| 2026-08-08 | TMO $594.00, RSI 71.6, up; 7D +3.43%; 30D +16.44%; 3M +27.87%; -10.27% from 52wk high. No new fundamentals re-researched. |
| 2026-08-14 | TMO $588.29, RSI 63.2, up; 7D -0.96%; 30D +9.90%; 3M +34.34%; -7.47% from 52wk high. No new fundamentals re-researched. |
| 2026-08-22 | TMO $629.27, RSI 74.6, strong-up; 7D +7.00%; 30D +19.53%; 3M +40.37%; -2.29% from 52wk high. 1Y +30.08%, vs SMA200 +17.90%. No new fundamentals re-researched. |
| 2026-08-28 | TMO $622.18, RSI 66.2, strong-up; 7D -1.14%; 30D +7.93%; 3M +26.33%; -3.84% from 52wk high. 1Y +27.04%, vs SMA200 +16.2%. No new fundamentals re-researched. |
| 2026-09-04 | TMO $613.78, RSI 57.4, strong-up; 7D -1.32%; 30D +6.22%; 3M +29.82%; -5.13% from 52wk high. 1Y +25.39%, vs SMA200 +14.50%. News not pulled for this move (last fetched 2026-07-29, well before this window). |
| 2026-09-11 | TMO $609.82, RSI 54.8, strong-up; 7D -0.65%; 30D +1.13%; 3M +29.93%; -5.75% from 52wk high. 1Y +24.1%, vs SMA200 +13.6% — still a deep pullback in an intact trend. No new filing this cycle. News not pulled for this move (last fetched 2026-07-29, now roughly six weeks stale). |
| 2026-09-18 | TMO $651.45, RSI 67.6, strong-up; 1D -1.04%; 7D +6.83%; 30D +6.18%; 3M +40.21%; -1.83% from 52wk high, the narrowest gap in this series. 1Y +35.41% with alpha1y +20.39 and price +21.1% above the 200-day — an intact long uptrend making a new leg, and the name joined the desk's extension board this week as a steady climber. Volume ran 2.22 times the average into Friday's quarterly options expiry. News pulled 2026-09-18: second-quarter results coverage (revenue $11.99B, +10%; adjusted EPS $6.03, +13%; raised full-year guidance; $1B buyback) and a reported $9.1B acquisition of Clario Holdings — all undated within this week, so nothing names this week's gain. Stock-events checked: no TMO row dated 2026-09-12 to 2026-09-18. No newly filed period on disk: the newest filed quarter ends 2026-03-28, so the second-quarter numbers in the news are not yet in the filing cache. |
| 2026-09-23 | TMO $665.30, RSI 71.5, strong-up; 1D +1.03%; 7D +2.60%; 30D +5.81%; 3M +35.17%; -0.92% from 52wk high. 1Y +41.63% with a one-year excess return of +25.86 points and price +23.4% above the 200-day — an intact long uptrend at its high, RSI above 70. Top rewritten with a flag-entry call keyed to the 2026-09-11 close ($609.82). Stock-events checked: no TMO row dated 2026-09-19 to 2026-09-23. News receipt written 2026-09-18 — news not pulled for the September 21–23 sessions. No newly filed period on disk: newest filed quarter still ends 2026-03-28 (10-Q filed 2026-05-01); the Q2 figures in the news are not in the filing cache. |
| 2026-09-28 | TMO $678.60, RSI 73.5, +6.8% vs SMA20, 30D +9.1%. The long trend remains intact; The newest verified quarter ends 2026-06-27 (filed 2026-07-31); revenue was $11.99B. Against 2025-06-28 revenue of $10.86B, that is +10.5% year over year. The news search for the latest move failed; the last completed search was on 2026-09-18. No company event for TMO was recorded between September 24 and 28. |
Sources
- Extension-board placement and the options-expiry note: 2026-09-18-monster-scan and 2026-09-17-market-brief.
- Q2 2026 coverage: Thermo Fisher release and GuruFocus call highlights.
- News receipt: latest (fetched 2026-09-18; items carry inferred dates).
- Scheduled-event check:
research/stock-events/— no TMO row dated 2026-09-12 to 2026-09-23. - Prior-cycle history: this file's dated update log.
2026-09-28 refresh receipts
2026-09-28 settled-close receipt: *, TMO row dated 2026-09-28; tape values above are bound to the current summary fields.
2026-09-28 financial-period check: income-statements and key-financials; newest verified 2026-06-27 period, filed 2026-07-31 (Massive statement / SEC period cross-check).
2026-09-28 news receipt check: latest, fetched 2026-09-18; receipt is not current; latest-session cause remains unassigned.
2026-09-28 stock-event scan:
research/stock-events/, no TMO row dated 2026-09-24 through 2026-09-28.2026-09-28 captured-follows scan: tweets has 0 September 24–28 document(s) tagging TMO.
Retrospective social-search receipt (captured 2026-09-29): 2026-09-29-social-search-tmo; quality/attention check only, not a September 28 event or price source.
2026-09-29 browser discovery check for TMO: news-discovery-google-sep29 (key
TMO); search links only, not evidence of an event or of absence of news.